Breaking News Instant updates and real-time market news.

WBT

Welbilt

$19.14

0.25 (1.32%)

, CDE

Coeur Mining

$8.48

0.12 (1.44%)

04:55
06/20/17
06/20
04:55
06/20/17
04:55

Goldman Sachs to hold a conference

Leveraged Finance Conference is being held in Palos Verdes, CA on June 19-20.

WBT

Welbilt

$19.14

0.25 (1.32%)

CDE

Coeur Mining

$8.48

0.12 (1.44%)

SABR

Sabre

$22.73

0.18 (0.80%)

UNIT

Uniti Group

$27.40

0.67 (2.51%)

VRX

Valeant

$13.47

0.81 (6.40%)

AMAG

Amag Pharmaceuticals

$16.65

0.25 (1.52%)

CRC

California Resources

$9.92

-0.44 (-4.25%)

HRI

Herc Holdings

$39.25

1.88 (5.03%)

AMKR

Amkor Technology

$10.80

0.24 (2.27%)

  • 20

    Jun

  • 20

    Jun

  • 22

    Jun

  • 26

    Jun

  • 03

    Aug

  • 24

    Aug

  • 13

    Sep

WBT Welbilt
$19.14

0.25 (1.32%)

CDE Coeur Mining
$8.48

0.12 (1.44%)

10/10/16
ROTH
10/10/16
NO CHANGE
Target $16
ROTH
Buy
Coeur Mining price target lowered to $16 from $17.50 at Roth Capital
Roth Capital analyst Joe Reagor noted that Coeur Mining's Q3 production came in below his estimates, but the company still raised full year guidance, as anticipated. Reagor cut his price target on Coeur to $16 from $17.50 to reflect the recent decline in precious metal prices, but maintains a Buy rating on the stock.
10/25/16
ADAM
10/25/16
INITIATION
Target $13
ADAM
Buy
Coeur Mining initiated with a Buy at Canaccord
Canaccord analyst Peter Bure initiated Couer Mining with a Buy rating and $13 price target as he believes silver prices will continue to appreciate over the next 12-18 months as zinc and lead mine closures impact supply.
10/03/16
DBAB
10/03/16
UPGRADE
DBAB
Hold
Coeur Mining upgraded to Hold from Sell at Deutsche Bank
08/30/16
CIBC
08/30/16
UPGRADE
CIBC
Sector Performer
Coeur Mining upgraded to Sector Performer from Underperformer at CIBC
SABR Sabre
$22.73

0.18 (0.80%)

04/07/17
COWN
04/07/17
NO CHANGE
COWN
Cowen travel agent survey positive for Sabre, Travelport and Expedia
Cowen conducted a travel agent survey to gauge trends on sentiment, demand for airline products, dynamics in the Global Distribution System marketplace, and participation in online travel affiliate programs. The agents skewed bullish overall and the survey was positive for Sabre (SABR), Travelport (TVPT), and Expedia (EXPE), the firm reported. The survey showed meaningful demand for economy products, controlled GDS incentive payment growth, and a majority of respondents said selling ancillary airline services is not financially worthwhile for them, Cowen's analysts noted.
04/06/17
MSCO
04/06/17
DOWNGRADE
Target $24
MSCO
Equal Weight
Sabre downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Brian Essex downgraded Sabre to Equal Weight and trimmed his price target to $24 from $26 due to investment spending that will pressure margin expansion and cash flow growth through mid 2018. Essex said Sabre is under-invested in its infrastructure and is making necessary investments to improve responsiveness, reliability and security of its platform going forward but lacks catalysts ahead that indicate better growth and leverage from investments.
02/20/17
BOFA
02/20/17
DOWNGRADE
BOFA
Neutral
Sabre downgraded to Neutral from Buy at BofA/Merrill
02/14/17
BOFA
02/14/17
DOWNGRADE
BOFA
Neutral
Sabre downgraded to Neutral from Buy at BofA/Merrill
UNIT Uniti Group
$27.40

0.67 (2.51%)

04/10/17
RHCO
04/10/17
NO CHANGE
RHCO
SunTrust views AT&T deal as highlighting 5G momentum
SunTrust analyst Greg Miller believes AT&T's (T) acquisition of Straight Path (STRP) highlights the "strong momentum" on early 5G network development plans, including fixed wireless. He believes the news is positive for infrastructure companies including Crown Castle (CCI), Zayo Group (ZAYO), Uniti Group (UNIT) and ultimately American Tower (AMT) and SBA Communications (SBAC) in later-stage 5G deployments.
04/11/17
RHCO
04/11/17
NO CHANGE
RHCO
Uniti Group acquisition positive, says SunTrust
After Uniti Group (UNIT) bought Southern Light, SunTrust analyst Greg Miller says that the deal enhances the value of the company's fiber assets and will diversify its revenue. The analyst admits that the company paid a high price, but he thinks it is worthwhile, given the value of the assets it acquired. He keeps a $30 price target and a Buy rating on the shares.
05/22/17
DBAB
05/22/17
INITIATION
Target $28
DBAB
Buy
Uniti Group initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Matthew Niknam started Uniti Group with a Buy rating and $28 price target.
06/19/17
RBCM
06/19/17
INITIATION
RBCM
Outperform
Uniti Group initiated with an Outperform at RBC Capital
RBC Capital analyst Jonathan Atkin started coverage of Uniti with a $32 price target and an Outperform rating. The analyst says that the company has "favorable organic and inorganic growth opportunities (compared with) its peers," partly due to its focus on smaller markets, its "broader customer base," and "strong valuation metrics."
VRX Valeant
$13.47

0.81 (6.40%)

06/19/17
WELS
06/19/17
NO CHANGE
WELS
Underperform
Wells says Paulson joining Valeant board likely a 'signal of dissatisfaction'
Wells Fargo analyst David Maris said that while some shareholders might see John Paulson joining Valeant's board as a vote of confidence, he "cannot help but think" this is a "signal of dissatisfaction of some sort." Maris, who maintains his long-held Underperform rating on Valeant, added that he does not know what new domain experience Paulson will bring to the board that was not already present.
06/16/17
CANT
06/16/17
INITIATION
Target $18
CANT
Overweight
Valeant initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Valeant Pharmaceuticals with an Overweight rating and $18 price target. The analyst believes Valeant can reduce its debt to manageable levels over the medium term and thinks new management can post earnings upside in 2019 and beyond. The analyst also thinks the negative media attention placed on the company has reduced significantly from a year ago.
06/14/17
RODM
06/14/17
NO CHANGE
Target $6
RODM
Buy
EyeGate price target lowered to $6 from $10 at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju lowered his price target for EyeGate Pharmaceuticals (EYEG( to $6 after the company granted a subsidiary of Valeant Pharmaceuticals (VRX) exclusive commercial and manufacturing rights to the EyeGate II Delivery System and EGP-437 combination product for treatment of post-operative pain and inflammation in ocular surgery patients. The analyst views the development, along with the top-line data from the first-in-human pilot trial of ocular bandage gel in patients with large corneal epithelial defects, as positive developments and raised his valuation of the company to $112M from $80M. His lowered target reflects higher shares outstanding. Selvaraju reiterates an Outperform rating on EyeGate.
06/09/17
WELS
06/09/17
NO CHANGE
WELS
Outperform
Wells says Valeant's focus on EBITDA ignores rising borrowing costs
After Valeant Pharmaceuticals issued a regulatory filing with financial data for its just sold iNova Pharmaceuticals unit, Wells Fargo analyst David Maris says that while the company is executing deals and reducing absolute debt, "leverage seems to be relatively unchanged." Valeant's focus on EBITDA versus earnings is to have investors "ignore the impact of increased borrowing costs and any impact from potential dilutive equity based financing," Maris tells investors in a research note. Valeant has indicated an equity raise is not off the table, the analyst adds. He has an Underperform rating on the stock with a $9 price target. Valeant in afternoon trading is down 26c to $13.00.
AMAG Amag Pharmaceuticals
$16.65

0.25 (1.52%)

01/31/17
JPMS
01/31/17
NO CHANGE
Target $24
JPMS
Neutral
AMAG Pharmaceuticals price target lowered to $24 from $33 at JPMorgan
JPMorgan analyst Jessica Fye lowered her price target for AMAG Pharmaceuticals to $24 following updates at her firm's healthcare conference, including the shift in Makena strategy, Rekynda in-licensing and 2017 guidance. The analyst keeps a Neutral rating on the shares.
02/03/17
COWN
02/03/17
DOWNGRADE
Target $25
COWN
Market Perform
AMAG Pharmaceuticals downgraded to Market Perform from Outperform at Cowen
Cowen analyst Ken Cacciatore downgraded AMAG Pharmaceuticals to Market Perform from Outperform on the belief that the franchise extension strategy for Makena will unfortunately fail. The analyst also questions the business decisions made after acquiring Makena, such as buying CBR, which could prove to be value destroying. Cacciatore lowered his price target to $25 from $35 on AMAG Pharmaceuticals shares.
03/15/17
RAJA
03/15/17
NO CHANGE
RAJA
Raymond James says new study highlights risks for AMAG
Raymond James analyst Christopher Raymond says a new study in the American Journal of Obstetrics and Gynecology questions the therapeutic utility of hydroxyprogesterone caproate for preterm birth also highlights a potential safety signal. Hydroxyprogesterone caproate is the active ingredient in AMAG Pharmaceuticals' Makena. The analyst has an Underpeform rating on the shares.
01/10/17
NEED
01/10/17
DOWNGRADE
NEED
Hold
AMAG Pharmaceuticals downgraded to Hold from Buy at Needham
CRC California Resources
$9.92

-0.44 (-4.25%)

11/22/16
MSCO
11/22/16
UPGRADE
MSCO
Equal Weight
California Resources upgraded to Equal Weight at Morgan Stanley
11/22/16
11/22/16
UPGRADE
Target $21

Equal Weight
California Resources upgraded to Equal Weight at Morgan Stanley
As previously reported, Morgan Stanley upgraded California Resources to Equal Weight from Underweight with a $21 price target. Analyst Evan Calio said California Resources has the highest leverage to crude ahead of the OPEC meeting on November 30, which drives a positive risk/reward into the end of the year.
HRI Herc Holdings
$39.25

1.88 (5.03%)

05/18/17
SIDC
05/18/17
DOWNGRADE
SIDC
Neutral
Herc Rentals downgraded to Neutral from Buy at Sidoti
04/10/17
KEYB
04/10/17
UPGRADE
KEYB
Overweight
Herc Rentals upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Joe Box upgraded Herc Rentals as he says that used prices have reached a positive turning point, possibly paving the way for "modest" increases in rental fees and increased certainty of cycle extension. He thinks that Herc's stock could potentially rise more than any other name in the group, given what he sees as the company's "industry-lagging operating statistics" and the potential for its EBITDA to jump 40% by 2021. Target $60.
04/06/17
NRCS
04/06/17
UPGRADE
NRCS
Buy
Herc Rentals upgraded to Buy from Neutral at Northcoast
02/07/17
02/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Restoration Hardware (RH) downgraded to Underperform from Neutral at Buckingham with the firm's analyst recommending using Restoration Hardware shares as a source of funds ahead of fourth quarter earnings March 30 as he expects a choppy road to recovery in fiscal 2017, marked by trade offs between revenus and margins. Further, Buckingham said liquidity issues could loom large in investors minds this year with its first tranche of $350M in convertible debt due in June 2019, combined with execution challenges, creates uncertainty around a potential earnings recovery. 2. Capstead Mortgage (CMO) downgraded to Market Perform from Outperform at Wells Fargo with analyst Joel Houck saying a modest dividend reduction in the near term can't be ruled out following the company's "disappointing" Q4 results. 3. Asanko Gold (AKG) downgraded to Hold from Speculative Buy at Canaccord with analyst Rahul Paul citing an update on its Asanko Gold mine expansion. The company indicated that mineral reserve is not expected to materially change, and as a result, the analyst lowered his expected reserve additions. 4. Haemonetics (HAE) downgraded to Market Perform from Outperform at Barrington with analyst Michael Petusky citing reduced expectations for next year following the company's third quarter results. The analyst thinks the shares are about fairly valued. 5. Herc Rentals (HRI) downgraded to Neutral from Buy at Northcoast with analyst John Healy saying shares have exceeded his price target of $48 and views risk/reward as balanced. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AMKR Amkor Technology
$10.80

0.24 (2.27%)

TODAY'S FREE FLY STORIES

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$204.65

1.99 (0.98%)

16:57
09/22/17
09/22
16:57
09/22/17
16:57
Hot Stocks
Allergan receives refusal to file letter from FDA for Vraylar »

Allergan announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

HON

Honeywell

$141.75

0.89 (0.63%)

, CC

Chemours

$51.79

-0.16 (-0.31%)

16:51
09/22/17
09/22
16:51
09/22/17
16:51
Hot Stocks
Honeywell, Chemours seek rehearing of D.C Court decision regarding SNAP program »

Honeywell (HON) and…

HON

Honeywell

$141.75

0.89 (0.63%)

CC

Chemours

$51.79

-0.16 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JOE

Saint Joe Co.

$18.60

0.45 (2.48%)

16:46
09/22/17
09/22
16:46
09/22/17
16:46
Hot Stocks
Breaking Hot Stocks news story on Saint Joe Co. »

Fairholme raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:40
09/22/17
09/22
16:40
09/22/17
16:40
General news
Moody's downgrades UK's rating to Aa2, changes outlook to stable »

Moody's Investors…

A

Agilent

$65.78

-0.14 (-0.21%)

, MRK

Merck

$65.13

-0.47 (-0.72%)

16:36
09/22/17
09/22
16:36
09/22/17
16:36
Hot Stocks
Agilent receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3 »

Agilent Technologies…

A

Agilent

$65.78

-0.14 (-0.21%)

MRK

Merck

$65.13

-0.47 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 08

    Nov

  • 30

    Nov

TYHT

Shineco

$3.23

-0.45 (-12.23%)

16:35
09/22/17
09/22
16:35
09/22/17
16:35
Hot Stocks
Shineco enters into strategic cooperation to establish Apocynum Industrial Park »

Shineco announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$1.16

0.03 (2.65%)

16:34
09/22/17
09/22
16:34
09/22/17
16:34
Hot Stocks
Appliance Recycling gets written notice of default »

On September 20,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNVA

Rennova Health

$0.22

0.0086 (4.07%)

16:31
09/22/17
09/22
16:31
09/22/17
16:31
Hot Stocks
Rennova Health announces 1 for 15 reverse stock split »

Rennova Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$1.16

0.03 (2.65%)

16:31
09/22/17
09/22
16:31
09/22/17
16:31
Hot Stocks
Breaking Hot Stocks news story on Appliance Recycling »

Appliance Recycling gets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
09/22/17
09/22
16:30
09/22/17
16:30
Options
Preliminary option volume of 13.9M today »

Preliminary option volume…

EKSO

Ekso Bionics

$1.28

0.14 (12.28%)

16:23
09/22/17
09/22
16:23
09/22/17
16:23
Hot Stocks
Ekso Bionics awarded government contract »

The Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

, AET

Aetna

$153.57

0.18 (0.12%)

16:22
09/22/17
09/22
16:22
09/22/17
16:22
General news
On The Fly: Top stock stories for Friday »

The major averages…

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CI

Cigna

$182.74

0.61 (0.33%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

FSLR

First Solar

$51.41

2.65 (5.43%)

FINL

Finish Line

$9.73

0.51 (5.53%)

ASND

Ascendis Pharma

$34.24

6.5 (23.43%)

VSAR

Versartis

$2.68

-18.925 (-87.62%)

ICPT

Intercept

$61.59

-12.11 (-16.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

DLR

Digital Realty

$114.51

-1.72 (-1.48%)

16:19
09/22/17
09/22
16:19
09/22/17
16:19
Syndicate
Breaking Syndicate news story on Digital Realty »

Digital Realty files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.